{"product_id":"pbh-bcg-matrix","title":"(PBH) Prestige Consumer Healthcare Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Prestige Consumer Healthcare Inc. BCG Matrix is a simple strategic tool used to classify the company’s products or business units into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHydralyte, oral rehydration, international expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHydralyte fits a Star: it plays in oral rehydration, hydration, wellness, and recovery, while Prestige Consumer Healthcare Inc. keeps widening U.S. distribution beyond its core international base. In fiscal 2025, Prestige generated about $250 million in net sales, and Hydralyte remains one of its clearest growth bets. That mix of category demand and expansion supports Star-style portfolio treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTheraTears, dry-eye care, screen-time demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheraTears sits in a growth pocket because screen use keeps dry-eye demand high; U.S. adults spend about 7 hours a day on screens, which sustains treatment need. Its premium eye-care position supports pricing power, but it still needs steady marketing and shelf support to defend share, which fits a Star profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDenTek, interdental care, oral-health growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDenTek fits Prestige Consumer Healthcare's Star logic because it sits in oral-care adjacencies where preventive use is still underpenetrated; U.S. dental spending was about $177 billion in 2024, and preventive products get more dentist support each year. Prestige reported fiscal 2025 net sales of about $1.1 billion, giving room to keep scaling DenTek with merchandizing and line extensions. The brand can ride dentist-recommended interdental care and expand faster than the core.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDebrox, earwax removal, self-care category\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDebrox fits Star logic because it is a recognized at-home earwax removal brand in a self-care category that people keep buying. Prestige Consumer Healthcare Inc. reported fiscal 2025 net sales of about $1.12 billion, and this kind of steady OTC demand helps support investment in brands with repeat use. Ear care is niche, but Debrox has enough brand pull to defend share and keep growing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecognized self-care brand\u003c\/li\u003e\n\u003cli\u003eFits at-home treatment demand\u003c\/li\u003e\n\u003cli\u003eSteady, not giant, category\u003c\/li\u003e\n\u003cli\u003eEnough traction for investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBoudreaux's Butt Paste, diaper rash care, baby segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBoudreaux's Butt Paste is one of Prestige Consumer Healthcare Inc.'s best-known baby-care brands, and diaper rash care is a repeat-use need that supports steady shelf demand. In FY2025, Prestige generated about $1.1 billion in net sales, so a trusted premium baby line can still add value through distribution gains and brand loyalty. If Prestige keeps defending share, Boudreaux's can stay a stable Stars-style asset in the baby segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring need supports repeat purchases.\u003c\/li\u003e\n\u003cli\u003eTrust and shelf space drive growth.\u003c\/li\u003e\n\u003cli\u003eShare defense keeps the brand strong.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrestige’s Star Brands Drive Repeat OTC Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars in Prestige Consumer Healthcare Inc.’s mix are Hydralyte, TheraTears, DenTek, Debrox, and Boudreaux's Butt Paste because they sit in repeat-use care niches with room to gain share. Fiscal 2025 net sales were about $1.1 billion to $1.12 billion, and that scale supports brand spend and shelf gains. Hydralyte and TheraTears lean on rising hydration and dry-eye demand, while DenTek, Debrox, and Boudreaux's benefit from steady OTC repurchase.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003cth\u003eFY2025 cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHydralyte\u003c\/td\u003e\n\u003ctd\u003eHydration, recovery\u003c\/td\u003e\n\u003ctd\u003eGrowth bet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTheraTears\u003c\/td\u003e\n\u003ctd\u003eDry-eye demand\u003c\/td\u003e\n\u003ctd\u003ePremium position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDenTek\u003c\/td\u003e\n\u003ctd\u003eOral-care adjacency\u003c\/td\u003e\n\u003ctd\u003eExpand share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebrox\u003c\/td\u003e\n\u003ctd\u003eRepeat OTC use\u003c\/td\u003e\n\u003ctd\u003eDefend brand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePrestige Consumer Healthcare’s BCG Matrix maps its brands into Stars, Cash Cows, Question Marks, and Dogs to guide invest\/hold\/divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG view of Prestige Consumer Healthcare Inc. to spot cash cows and weak spots fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists trusted sources for Prestige Consumer Healthcare Inc., making the analysis easier to verify, defend, and use for faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClear Eyes, eye redness relief, mature shelf staple\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClear Eyes is a long-running OTC eye-drop brand with strong shelf recognition and steady repeat use. In Prestige Consumer Healthcare's FY2025, net sales were about $1.1 billion, and mature eye-care brands like Clear Eyes help fund growth elsewhere. With limited category growth but durable awareness, Clear Eyes fits the Cash Cow slot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMonistat, antifungal treatment, category leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMonistat is a category leader in vaginal antifungal care, and its repeat-use model fits a Cash Cow. Prestige Consumer Healthcare Inc. reported roughly $1.1 billion in fiscal 2025 net sales, with mature brands like Monistat helping support steady cash generation. Because the category is stable and low-growth, Prestige can harvest cash without heavy growth spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDramamine, motion sickness, travel staple\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDramamine is Prestige Consumer Healthcare Inc.'s classic motion-sickness cash cow, with steady demand tied to travel, not fast category growth. In fiscal 2025, Prestige Consumer Healthcare Inc. generated about $1.1 billion in net sales, and brands like Dramamine help support that cash flow with modest promotion. As travel volumes hold up, this franchise stays a low-drama, repeat-purchase brand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompound W, wart removal, steady OTC demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompound W is a long-standing wart-removal brand with broad household recognition, so it fits a Cash Cow role in Prestige Consumer Healthcare’s BCG mix. Wart care is a small, mature OTC niche, which limits growth but supports steady repeat demand and dependable cash flow. That means the brand needs far less heavy investment than newer growth bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy brand, high awareness\u003c\/li\u003e\n\u003cli\u003eMature OTC niche, low growth\u003c\/li\u003e\n\u003cli\u003eSteady demand, strong cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBC\/Goody's, analgesic powders, legacy pain relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBC and Goody's are legacy OTC analgesic powders in a mature U.S. pain-relief market, so they fit the Cash Cow slot: steady repeat use, strong brand recall, and limited growth. Prestige Consumer Healthcare posted about $1.14 billion in fiscal 2025 net sales, and these brands help support that cash flow even as category growth stays low. Their role is defensive, not expansion-led.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh repeat purchase\u003c\/li\u003e\n\u003cli\u003eStrong historical awareness\u003c\/li\u003e\n\u003cli\u003eLow growth, high cash yield\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrestige’s OTC Cash Cows: Steady Brands, Steady Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrestige Consumer Healthcare Inc.’s Cash Cows are mature OTC brands that keep selling with little growth spend. In fiscal 2025, the Company generated about $1.1 billion in net sales, and brands like Clear Eyes, Monistat, Dramamine, Compound W, and BC and Goody's helped turn steady demand into cash. Their low-growth niches make them reliable profit engines, not expansion bets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eCash Cow fit\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClear Eyes\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eStrong awareness, repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonistat\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eCategory leader, steady demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDramamine\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eTravel-linked, mature niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003ePrestige Consumer Healthcare Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Prestige Consumer Healthcare Inc. BCG Matrix preview you’re viewing is the exact same file you’ll receive after purchase. No demo content, no watermarks—just the complete, ready-to-use report. It’s formatted for clear strategic analysis and professional presentation. Once purchased, the full document is instantly available for download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuden's, cough lozenges, small OTC share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuden's is a small OTC brand in a crowded cough and cold aisle, with no public sign of strong share gain. Prestige Consumer Healthcare reported FY2025 net sales of about $1.15 billion, but it does not break out Luden's sales, which suggests limited scale. With weak growth momentum and shelf pressure from larger rivals, Luden's fits BCG Dog status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFess, saline nasal wash, niche international\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFess is a niche saline nasal wash with limited scale outside Prestige Consumer Healthcare Inc.’s core markets. In nasal care, brands face easy switching and heavy competition from large OTC players, so weak share and slow growth fit Dog status. Prestige Consumer Healthcare Inc. places it in a low-growth, low-share corner of the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNix, lice treatment, shrinking category\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNix sits in a shrinking, low-growth lice-treatment niche, so it is not a major growth engine for Prestige Consumer Healthcare Inc. Head lice cases are episodic, not steady, and the CDC estimates 6 million to 12 million U.S. infestations a year in children ages 3-11, which makes demand choppy and highly seasonal. With easy OTC substitutes and heavy price pressure, Nix is more of a weak cash contributor than a durable winner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGaviscon, antacid care, crowded competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGaviscon sits in a crowded antacid aisle where price and brand familiarity drive most buys, so it faces pressure from cheaper store brands and bigger names like Tums and Pepcid. That keeps growth muted and share limited in key markets, making it a weaker BCG candidate versus Prestige Consumer Healthcare Inc.’s stronger brands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh shelf clutter\u003c\/li\u003e\n\u003cli\u003ePrice-sensitive switching\u003c\/li\u003e\n\u003cli\u003eLow share, low growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSummer's Eve, feminine hygiene wash, low growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSummer's Eve is a mature feminine-hygiene brand in a steady, low-growth category, so it fits Prestige Consumer Healthcare Inc.'s Dog quadrant more than the growth buckets. With no clear share advantage, the brand’s upside is limited versus faster-moving lines. In FY2025, this kind of flat-demand franchise usually gets held for cash, not expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth limits new upside\u003c\/li\u003e\n\u003cli\u003eMature brand, weak share edge\u003c\/li\u003e\n\u003cli\u003eBest viewed as cash-generative\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrestige’s Dogs: Low-Share Brands Stuck in Slow-Growth Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrestige Consumer Healthcare Inc.’s Dogs are low-share, low-growth brands that mostly throw off cash, not expansion. FY2025 net sales were about $1.15 billion, but Luden's, Fess, Nix, Gaviscon, and Summer's Eve were all in crowded, mature niches with weak growth. That makes them the weakest BCG fit in the portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eDog cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLuden's\u003c\/td\u003e\n\u003ctd\u003eSmall OTC share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFess\u003c\/td\u003e\n\u003ctd\u003eNiche saline use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNix\u003c\/td\u003e\n\u003ctd\u003eChoppy demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChloraseptic, sore-throat sprays, seasonal upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChloraseptic has strong shelf recognition, but sore-throat demand still swings with cold and flu season, so sales are uneven. Prestige Consumer Healthcare reported about $1.1 billion in FY2025 net sales, but this brand still needs a bigger share of that base through better retail visibility and line extensions. Until those gains show up, Chloraseptic fits the Question Mark box: decent awareness, limited growth proof.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFleet, bowel-care extensions, aging-demand tailwind\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFleet is a Question Mark because bowel-care demand should rise with aging: the U.S. had about 62 million people age 65+ in 2025, and older adults use laxatives more often. Prestige can benefit from self-care habits, but Fleet sits in a fragmented market with strong store brands and OTC rivals. Growth depends on widening share, not just category tailwind. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHydralyte U.S. retail buildout, low current penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHydralyte has stronger traction in Australia and other international markets, but its U.S. retail base is still small. The U.S. hydration and electrolyte market is a multibillion-dollar category, so even low share can turn into meaningful upside for Prestige Consumer Healthcare Inc. if distribution expands. That gap makes Hydralyte a classic Question Mark: high market potential, but still limited U.S. penetration and an open path to win share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTheraTears Preservative-Free, premium eye-care line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTheraTears Preservative-Free sits in a Question Mark spot: preservative-free dry-eye care is a growth niche, and dry eye affects over 38 million U.S. adults. If premium formats keep gaining share, this line can scale fast, but right now it still lacks the volume to be a Star for Prestige Consumer Healthcare Inc.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth niche, but small base\u003c\/li\u003e\n\u003cli\u003ePremium adoption can lift sales\u003c\/li\u003e\n\u003cli\u003eNeeds more scale before Star status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDenTek aligner-care and whitening extensions, adjacent oral care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDenTek’s aligner-care and whitening lines fit adjacent oral care: they meet faster-growing needs, but DenTek still lacks clear category leadership. Prestige Consumer Healthcare may need heavier spend on shelf space, ads, and innovation to turn these into BCG \"question marks\" into winners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing demand, weak share\u003c\/li\u003e\n\u003cli\u003eNeeds brand and shelf investment\u003c\/li\u003e\n\u003cli\u003eUpside if repeat buys rise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrestige’s Question Mark Brands Need Share Gains to Move the Needle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChloraseptic, Fleet, Hydralyte, TheraTears Preservative-Free, and DenTek are Question Marks: each has clear demand, but Prestige Consumer Healthcare Inc. has not yet turned that into category-leading share. In FY2025, Prestige Consumer Healthcare Inc. posted about $1.1 billion in net sales, so these brands need share gains to move the needle.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eWhy it is a Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChloraseptic\u003c\/td\u003e\n\u003ctd\u003eStrong awareness, seasonal demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFleet\u003c\/td\u003e\n\u003ctd\u003eOlder population helps, share is weak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234821415177,"sku":"pbh-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pbh-bcg-matrix.webp?v=1785728230","url":"https:\/\/dcfanalyst.com\/products\/pbh-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}